Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LZ901 Phase 3 in Adults ≥40 Years for Herpes Zoster
NCT06088745Phase 3Recruiting
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LZ901 in herpes zoster (HZ) (4 arms), sponsored by Beijing Luzhu Biotechnology. Primary endpoint: Vaccine Efficacy. Started Sep 2023; status: recruiting.
02
Drugs
LZ901
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06088745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088745.